Laboratory Medicine ›› 2016, Vol. 31 ›› Issue (12): 1081-1086.DOI: 10.3969/j.issn.1673-8640.2016.12.016
• Orginal Article • Previous Articles Next Articles
KANG Juan
Received:
2016-01-09
Online:
2016-12-25
Published:
2016-12-29
CLC Number:
KANG Juan. Introduction on protein value-transfer procedure using cystatin C as an example[J]. Laboratory Medicine, 2016, 31(12): 1081-1086.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2016.12.016
项目 | R1 | R2 | R3* | R4* | R5* | R6* |
---|---|---|---|---|---|---|
ERM-DA471(g) | 0.200 0 | 0.500 0 | 0.390 0(R2) | 0.300 0(R3) | 0.200 0(R4) | 0.100 0(R5) |
稀释缓冲液(g) | 0.000 0 | 0.125 0 | 0.130 0 | 0.150 0 | 0.200 0 | 0.100 0 |
稀释因子 | 1.000 0 | 0.800 0 | 0.750 0 | 0.666 7 | 0.500 0 | 0.500 0 |
预稀释因子 | 1.000 0 | 1.000 0 | 0.800 0 | 0.600 0 | 0.400 0 | 0.200 0 |
理论相对浓度(%) | 100.00 | 80.00 | 60.00 | 40.00 | 20.00 | 10.00 |
项目 | R1 | R2 | R3* | R4* | R5* | R6* |
---|---|---|---|---|---|---|
ERM-DA471(g) | 0.200 0 | 0.500 0 | 0.390 0(R2) | 0.300 0(R3) | 0.200 0(R4) | 0.100 0(R5) |
稀释缓冲液(g) | 0.000 0 | 0.125 0 | 0.130 0 | 0.150 0 | 0.200 0 | 0.100 0 |
稀释因子 | 1.000 0 | 0.800 0 | 0.750 0 | 0.666 7 | 0.500 0 | 0.500 0 |
预稀释因子 | 1.000 0 | 1.000 0 | 0.800 0 | 0.600 0 | 0.400 0 | 0.200 0 |
理论相对浓度(%) | 100.00 | 80.00 | 60.00 | 40.00 | 20.00 | 10.00 |
项目 | T1 | T2 | T3* | T4* | T5* | T6* |
---|---|---|---|---|---|---|
候选标准物质(g) | 0.300 0 | 0.660 0 | 0.510 0(T2) | 0.360 0(T3) | 0.240 0(T4) | 0.150 0(T5) |
稀释缓冲液(g) | 0.000 0 | 0.165 0 | 0.170 0 | 0.180 0 | 0.240 0 | 0.150 0 |
稀释因子 | 1.000 0 | 0.800 0 | 0.750 0 | 0.666 7 | 0.500 0 | 0.500 0 |
预稀释因子 | 1.000 0 | 1.000 0 | 0.800 0 | 0.600 0 | 0.400 0 | 0.200 0 |
理论相对浓度(%) | 100.00 | 80.00 | 60.00 | 40.00 | 20.00 | 10.00 |
项目 | T1 | T2 | T3* | T4* | T5* | T6* |
---|---|---|---|---|---|---|
候选标准物质(g) | 0.300 0 | 0.660 0 | 0.510 0(T2) | 0.360 0(T3) | 0.240 0(T4) | 0.150 0(T5) |
稀释缓冲液(g) | 0.000 0 | 0.165 0 | 0.170 0 | 0.180 0 | 0.240 0 | 0.150 0 |
稀释因子 | 1.000 0 | 0.800 0 | 0.750 0 | 0.666 7 | 0.500 0 | 0.500 0 |
预稀释因子 | 1.000 0 | 1.000 0 | 0.800 0 | 0.600 0 | 0.400 0 | 0.200 0 |
理论相对浓度(%) | 100.00 | 80.00 | 60.00 | 40.00 | 20.00 | 10.00 |
项目 | R1 | R2 | R3* | R4* | R5* | R6* |
---|---|---|---|---|---|---|
ERM-DA471(g)# | 0.200 0 | 0.517 4 | 0.389 2(R2) | 0.296 7(R3) | 0.206 8(R4) | 0.101 0(R5) |
稀释缓冲液(g) | 0.000 0 | 0.123 0 | 0.128 9 | 0.149 4 | 0.198 8 | 0.099 5 |
稀释因子 | 1.000 0 | 0.807 9 | 0.751 2 | 0.665 1 | 0.509 9 | 0.503 7 |
预稀释因子 | 1.000 0 | 1.000 0 | 0.807 9 | 0.606 9 | 0.403 7 | 0.205 8 |
理论相对浓度(%) | 100.0 | 80.79 | 60.69 | 40.37 | 20.58 | 10.37 |
项目 | R1 | R2 | R3* | R4* | R5* | R6* |
---|---|---|---|---|---|---|
ERM-DA471(g)# | 0.200 0 | 0.517 4 | 0.389 2(R2) | 0.296 7(R3) | 0.206 8(R4) | 0.101 0(R5) |
稀释缓冲液(g) | 0.000 0 | 0.123 0 | 0.128 9 | 0.149 4 | 0.198 8 | 0.099 5 |
稀释因子 | 1.000 0 | 0.807 9 | 0.751 2 | 0.665 1 | 0.509 9 | 0.503 7 |
预稀释因子 | 1.000 0 | 1.000 0 | 0.807 9 | 0.606 9 | 0.403 7 | 0.205 8 |
理论相对浓度(%) | 100.0 | 80.79 | 60.69 | 40.37 | 20.58 | 10.37 |
项目 | T1 | T2 | T3* | T4* | T5* | T6* |
---|---|---|---|---|---|---|
候选标准物质(g) | 0.300 0 | 0.667 1 | 0.514 5(T2) | 0.363 8(T3) | 0.222 5(T4) | 0.151 4(T5) |
稀释缓冲液(g) | 0.000 0 | 0.163 0 | 0.169 0 | 0.179 4 | 0.235 4 | 0.150 1 |
稀释因子 | 1.000 0 | 0.803 6 | 0.752 7 | 0.669 7 | 0.485 9 | 0.502 2 |
预稀释因子 | 1.000 0 | 1.000 0 | 0.803 6 | 0.604 9 | 0.405 1 | 0.196 9 |
理论相对浓度(%) | 100.0 | 80.36 | 60.49 | 40.51 | 19.69 | 9.886 |
项目 | T1 | T2 | T3* | T4* | T5* | T6* |
---|---|---|---|---|---|---|
候选标准物质(g) | 0.300 0 | 0.667 1 | 0.514 5(T2) | 0.363 8(T3) | 0.222 5(T4) | 0.151 4(T5) |
稀释缓冲液(g) | 0.000 0 | 0.163 0 | 0.169 0 | 0.179 4 | 0.235 4 | 0.150 1 |
稀释因子 | 1.000 0 | 0.803 6 | 0.752 7 | 0.669 7 | 0.485 9 | 0.502 2 |
预稀释因子 | 1.000 0 | 1.000 0 | 0.803 6 | 0.604 9 | 0.405 1 | 0.196 9 |
理论相对浓度(%) | 100.0 | 80.36 | 60.49 | 40.51 | 19.69 | 9.886 |
测试结果 | T1 | T2 | T3 | T4 | T5 | T6 | C |
---|---|---|---|---|---|---|---|
第1个循环 | |||||||
第1次测试 | 80.76 | 64.59 | 48.24 | 32.21 | 16.49 | 10.37 | 50.49 |
第2次测试 | 81.56 | 65.03 | 48.24 | 32.24 | 16.49 | 10.37 | 50.93 |
均值 | 81.16 | 64.81 | 48.24 | 32.23 | 16.49 | 10.37 | 50.71 |
第2个循环 | |||||||
第1次测试 | 80.81 | 64.43 | 47.85 | 32.54 | 16.63 | 10.37 | 51.24 |
第2次测试 | 81.19 | 64.38 | 48.32 | 32.32 | 16.48 | 10.37 | 50.86 |
均值 | 81.00 | 64.41 | 48.09 | 32.43 | 16.56 | 10.37 | 51.05 |
第3个循环 | |||||||
第1次测试 | 82.22 | 64.67 | 46.31 | 31.37 | 16.85 | 11.49 | 50.10 |
第2次测试 | 81.57 | 64.64 | 47.03 | 30.79 | 17.10 | 10.96 | 49.99 |
均值 | 81.90 | 64.66 | 46.67 | 31.08 | 16.98 | 11.23 | 50.05 |
总均值(Y)* | 81.35 | 64.62 | 47.67 | 31.91 | 16.67 | 10.66 | 50.60 |
Y-3s | 79.92 | 64.01 | 45.07 | 29.73 | 15.88 | 9.17 | 49.07 |
Y+3s | 82.78 | 65.24 | 50.26 | 34.09 | 17.46 | 12.14 | 52.14 |
测试结果 | T1 | T2 | T3 | T4 | T5 | T6 | C |
---|---|---|---|---|---|---|---|
第1个循环 | |||||||
第1次测试 | 80.76 | 64.59 | 48.24 | 32.21 | 16.49 | 10.37 | 50.49 |
第2次测试 | 81.56 | 65.03 | 48.24 | 32.24 | 16.49 | 10.37 | 50.93 |
均值 | 81.16 | 64.81 | 48.24 | 32.23 | 16.49 | 10.37 | 50.71 |
第2个循环 | |||||||
第1次测试 | 80.81 | 64.43 | 47.85 | 32.54 | 16.63 | 10.37 | 51.24 |
第2次测试 | 81.19 | 64.38 | 48.32 | 32.32 | 16.48 | 10.37 | 50.86 |
均值 | 81.00 | 64.41 | 48.09 | 32.43 | 16.56 | 10.37 | 51.05 |
第3个循环 | |||||||
第1次测试 | 82.22 | 64.67 | 46.31 | 31.37 | 16.85 | 11.49 | 50.10 |
第2次测试 | 81.57 | 64.64 | 47.03 | 30.79 | 17.10 | 10.96 | 49.99 |
均值 | 81.90 | 64.66 | 46.67 | 31.08 | 16.98 | 11.23 | 50.05 |
总均值(Y)* | 81.35 | 64.62 | 47.67 | 31.91 | 16.67 | 10.66 | 50.60 |
Y-3s | 79.92 | 64.01 | 45.07 | 29.73 | 15.88 | 9.17 | 49.07 |
Y+3s | 82.78 | 65.24 | 50.26 | 34.09 | 17.46 | 12.14 | 52.14 |
检测方法 | 第1组 | 第2组 | 第3组 | 第4组 | 均值(mg/L) | CV(%) |
---|---|---|---|---|---|---|
PETIA | 4.35 | 4.40 | 4.43 | 4.47 | 4.41 | 1.3 |
PENIA | 4.47 | 4.60 | 4.46 | 4.54 | 4.52 | 1.5 |
检测方法 | 第1组 | 第2组 | 第3组 | 第4组 | 均值(mg/L) | CV(%) |
---|---|---|---|---|---|---|
PETIA | 4.35 | 4.40 | 4.43 | 4.47 | 4.41 | 1.3 |
PENIA | 4.47 | 4.60 | 4.46 | 4.54 | 4.52 | 1.5 |
1 | JOHNSON AM,WHICHER JT,LEDUE TB,et al. Effect of a new international reference preparation for proteins in human serum(certified reference material 470) on results of the College of American Pathologists Surveys for plasma proteins[J]. Arch Pathol Lab Med,2000,124(10):1496-1501. |
2 | JOHNSON AM,WHICHER JT. Effect of certified reference material 470(CRM 470) on national quality assurance programs for serum proteins in Europe[J]. Clin Chem Lab Med,2001,39(11):1123-1128. |
3 | 唐文佳,吴炯. 特定蛋白检测标准化——从CRM 470到ERM-DA470k及ERM-DA472k[J]. 检验医学,2012,27(4):237-242. |
4 | BLIRUP-JENSEN S. Protein standardization Ⅰ:protein purification procedure for the purification of human prealbumin,orosomucoid and transferrin as primary protein preparations[J]. Clin Chem Lab Med,2001,39(11):1076-1089. |
5 | BLIRUP-JENSEN S. Protein standardization Ⅱ:dry mass determination procedure for the determination of the dry mass of a pure protein preparation[J]. Clin Chem Lab Med,2001,39(11):1090-1097. |
6 | BLIRUP-JENSEN S. Protein standardization Ⅲ:method optimization basic principles for quantitative determination of human serum proteins on automated instruments based on turbidimetry or nephelometry[J]. Clin Chem Lab Med,2001,39(11):1098-1109. |
7 | BLIRUP-JENSEN S,JOHNSON AM,LARSEN M. Protein standardization Ⅳ:value transfer procedure for the assignment of serum protein values from a reference preparation to a target material[J]. Clin Chem Lab Med,2001,39(11):1110-1122. |
8 | BLIRUP-JENSEN S,JOHNSON AM,LARSEN M,et al. Protein standardization Ⅴ:value transfer. A practical protocol for the assignment of serum protein values from a reference material to a target material[J]. Clin Chem Lab Med,2008,46(10):1470-1479. |
9 | REIMER CB,SMITH SJ,WELLS TW,et al. Collaborative calibration of the U.S. National and the College of American Pathologists reference preparation for specific serum proteins[J]. Am J Clin Pathol,1982,77(1):12-19. |
10 | THOLEN DW,HOMBURGER HA. Assigning concentration estimates for the CAP reference preparation for serum proteins[J]. Pathologist,1984,38:226-228. |
11 | FINNEY DJ.Statistical methods in biological assay[M]. 3rd ed. New York:MacMillan,1978:69-1104. |
12 | REIMER CB,SMITH SF,HANNON WH,et al. Progress towards international reference standards for human serum proteins[J]. J Biol Stand,1978,6(2):133-158. |
13 | GRUBB A,BLIRUP-JENSEN S,LINDSTRM V,et al. First certified reference material for cystatin C in human serum ERM-DA471/IFCC[J]. Clin Chem Lab Med,2010,48(11):1619-1621. |
14 | GRUBB A,HORIO M,HANSSON LO,et al. Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator[J]. Clin Chem,2014,60(7):974-986. |
15 | 国秀芝,吴洁,侯立安,等. 五种可溯源胱抑素C检测系统结果的一致性评价[J]. 中华检验医学杂志,2014,37(5):365-370. |
16 | 康娟,王军,李彦超,等. 胱抑素C国家标准物质的研制[J]. 中华检验医学杂志,2013,36(10):942-946. |
17 | 张传宝,赵海建,曾洁,等. 胱抑素C标准物质ERM-DA 471/IFCC的互通性研究[J].中华检验医学杂志,2015,38(5):306-309. |
[1] | WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817. |
[2] | YANG Yuqiang, QUAN Xiaoli, WANG Liuyu, XIAN Wenfeng, YANG Hong. Expression of RRBP1 in osteosarcoma tissues and its effect on cell biological characteristics [J]. Laboratory Medicine, 2023, 38(9): 842-848. |
[3] | CHENG Xu, YANG Cunqing, PANG Bo, GU Chun, HOU Xueyun, FEI Jiaxin, WU Min, LI Jun, LIU Guijian. Number and activity of peripheral blood eosinophils in obese people [J]. Laboratory Medicine, 2023, 38(9): 855-859. |
[4] | FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883. |
[5] | ZHAO Jing, LI Yongqin, LI Yan, FAN Weiguang, YANG Xuegang. Roles of IP-10,SAA,hs-CRP,PCT and CD4+ T cell count determinations in HIV/AIDS patients with opportunistic infection [J]. Laboratory Medicine, 2023, 38(8): 725-729. |
[6] | WANG Yuemei, LI Lei. Clinical roles of nuclear matrix protein 22 and Atyp.C parameter in diagnosis of bladder cancer [J]. Laboratory Medicine, 2023, 38(8): 738-741. |
[7] | ZHAO Yanan, CAO Qixin, YAN Yan, LI Xiaocong, ZHAO Jianping, XIAO Weili. Research progress of CRISPR/Cas13 system for pathogen detection [J]. Laboratory Medicine, 2023, 38(8): 800-804. |
[8] | Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine , Molecular Diagnostics Society of Shanghai Medical Association , Tumor Immunology Branch of Shanghai Society for Immunology , Yueyang Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai University of Traditional Chinese Medicine , Shanghai Center for Clinical Laboratory, Clinical Laboratory Society of Chinese Association of Integrative Medicine , Clinical Laboratory Society of Shanghai Anticancer Association , Tumor Markers Society of Shanghai Anticancer Association . Expert consensus on the clinical application of AFP,AFP-L3% and DCP using GALAD and GALAD-like models in hepatocellular carcinoma [J]. Laboratory Medicine, 2023, 38(7): 607-623. |
[9] | ZHU Rixiang, YIN Jie. Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer [J]. Laboratory Medicine, 2023, 38(7): 629-633. |
[10] | CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639. |
[11] | PAN Xin, LÜ Ying, LI Yang, LI Rongguo. Effects of miR-24-3p targeting CHD5 on migration,invasion and radiosensitivity of thyroid cancer cells [J]. Laboratory Medicine, 2023, 38(7): 640-646. |
[12] | MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(7): 659-664. |
[13] | CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578. |
[14] | WU Caorong, CUI Wen, TANG Binbin, HE Jingjing, LAI Zhikun. Correlations between the ratio of C-reactive protein to prealbumin and the prognosis of patients with acute heart failure [J]. Laboratory Medicine, 2023, 38(6): 579-583. |
[15] | WANG Yang, MO Huifang, SHEN Ruojian, SHEN Yifeng, WANG Beili, PAN Baishen, GUO Wei. Analysis on the difference of lipoprotein(a) particle concentration and mass concentration in certain disease states [J]. Laboratory Medicine, 2023, 38(5): 405-412. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||